Introduced

Passed House

Passed Senate

Became law

Adjourned sine die. The bill was pending when the session ended, so it did not pass.

Last action · February 10, 2026

To Health Services (H)

Introduced February 3, 2026

House

Adjourned Sine Die

2026 Regular Session

HB543

AN ACT relating to the use of experimental treatments for life-threatening or severely debilitating illness.

Create a new section of KRS Chapter 217 to define terms; permit a manufacturer operating within an eligible facility to make available to an eligible patient an individualized investigational drug, biological product, or device; permit the manufacturer to provide the individualized investigational drug, biological product, or device or require the patient to cover the costs; provide that if a patient dies while being treated his or her heirs are not liable for costs; provide that…

Diseases Drugs and Medicines Health and Medical Services Health Care Professionals Hospitals And Health Facilities Nurses Pharmacists Physicians Research

Read the full text Kentucky Legislature LegiScan

AI-generated. Always verify with primary sources

Plain-language summary

Beta

This bill would allow manufacturers to make experimental drugs, biological products, or medical devices available to patients with life-threatening or severely debilitating illnesses outside of the standard approval process. It sets rules about who can access these treatments, protects doctors and other health care providers from losing their licenses for recommending them, and shields manufacturers from lawsuits if they acted with reasonable care. The bill also clarifies that insurers would not be required to cover…

Open official bill text (PDF)·Report a problem with the summary